— Registration now open for February 1 “Early Insights” webinar —
— Public comment period now open until February 22, 2022 —
BOSTON, January 25, 2022 – The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of plinabulin (BeyondSpring Pharmaceuticals) and trilaciclib (Cosela™, G1 Therapeutics) for the prevention of chemotherapy-induced neutropenia and other myelosuppressive effects.
This is a preliminary draft of ICER’s assessment of these treatments, and the findings within this document should not be interpreted to be ICER’s final conclusions.
Register for ICER’s Early Insights Webinar
On February 1, 2022, as part of ICER’s Early Insights Webinar Series, Dan Ollendorf, Director of Value Measurement & Global Health Initiatives at Tufts CEVR, will present the initial findings of this draft report. This webinar is exclusively available to all users of the ICER Analytics platform; registration for the webinar is now open.
Submit a Public Comment
The Draft Evidence Report is now open to public comment. All stakeholders are invited to submit formal comments by email to firstname.lastname@example.org, which must be received by 5 PM ET on February 22, 2022. Please submit public comments as a Word document in the following format:
- 12-point Times New Roman font
- Five-page maximum (not including references or appendices)
ICER will review all comments and incorporate any necessary changes in the Evidence Report and Revised Voting Questions that will be posted on or about March 17, 2022. All comments and ICER’s response to comments will be posted publicly along with the Evidence Report.
On December 1st, BeyondSpring Pharmaceuticals received a Complete Response Letter for plinabulin. Therefore, ICER has cancelled our public meeting, and will conclude this assessment with the revised Evidence Report that will be posted on March 17th.
The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system. For more information about ICER, please visit ICER’s website.